3,809 Shares in Boston Scientific Corporation $BSX Bought by PharVision Advisers LLC

Key Points

• PharVision Advisers LLC acquired 3,809 shares of Boston Scientific Corporation, valued at approximately $384,000, indicating institutional interest in the medical equipment provider.
• Analysts have raised price targets for Boston Scientific, with Truist Financial and Morgan Stanley setting new targets of $125.00, signaling a bullish outlook.
• Boston Scientific reported better-than-expected earnings of $0.75 per share for the latest quarter, surpassing the consensus estimate and achieving a 22.8% revenue increase compared to the previous year.

PharVision Advisers LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,809 shares of the medical equipment provider's stock, valued at approximately $384,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. 1248 Management LLC purchased a new stake in Boston Scientific in the 1st quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at about $27,000. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the 4th quarter valued at about $25,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. Finally, Sunbeam Capital Management LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at $18,802,597.06. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 over the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 0.9%

BSX stock traded up $0.92 during midday trading on Monday, hitting $108.14. 7,454,396 shares of the company's stock were exchanged, compared to its average volume of 5,736,611. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $108.94. The firm has a 50 day moving average price of $104.78 and a 200-day moving average price of $102.18. The stock has a market capitalization of $160.23 billion, a price-to-earnings ratio of 64.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. Morgan Stanley lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Wells Fargo & Company boosted their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Barclays boosted their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Robert W. Baird boosted their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.